Age: 56.0
Sex: M
Vaccine: COVID19
Symptoms: Blood test, Computerised tomogram, Diplopia, Investigation, Magnetic resonance imaging
Clinical narrative: Caller stated he went to an eye specialist and it was determined that he has Myasthenia Gravis concentrated in his eyes; Caller reported he began having double vision around Jul2021; This is a spontaneous report received from a contactable reporter(s) (Pharmacist) from medical information team. The reporter is the patient.  A 57 year-old male patient received bnt162b2 (BNT162B2), administered in arm left, administration date 17Feb2021 (Lot number: EN6201, Expiration Date: Unknown) at the age of 56 years as dose 2, single and administered in arm left, administration date 27Jan2021 (Lot number: EL9262) as dose 1, single for covid-19 immunisation. The patient had no relevant medical history. There were no concomitant medications. The following information was reported: MYASTHENIA GRAVIS (medically significant) with onset Jul2021, outcome "unknown", described as "Caller stated he went to an eye specialist and it was determined that he has Myasthenia Gravis concentrated in his eyes"; DIPLOPIA (disability) with onset Jul2021, outcome "unknown", described as "Caller reported he began having double vision around Jul2021". Patient asked were there any reports of this happening to other people. He went to an eye specialist and did some blood tests. He had a MuSK test done. The MuSK test came out very high for Myasthenia gravis. Which was what the eye doctor suspected. The eye doctor referred him to a neurologist. He had Myasthenia gravis, and it was small like with his eyes. He was experiencing all of his symptoms in his eyes. It was concentrated in his eyes. His eyes will freeze, or he will see things in multiple visions. He had began treatment with a neurologist. He just wanted to bring this to Pfizer's attention. He was wondering if Pfizer had any information on anyone going through this same situation. In Sep2021, he was at his Neurologist, and the neurologist prescribed Mestinon. He started at half a tablet 3 times a day, and then he went to one tablet 3 times a day, and then this month Jan2022 he went up to 4 tablets a day. They did surgery and removed his thymus glad on 02Dec2021. They did surgery because his MuSK test came back so high. It was 21.5, and it is supposed to be like 0.05 or something. They have done a lot of MRIs and CAT scans. They recommended he get his thymus gland removed with Myasthenia gravis. The patient underwent the following laboratory tests and procedures: blood tests: (2021) unknown result; CAT scans: (2021) unknown result; MuSK test: (2021) 21.5, notes: came out very high for Myasthenia gravis; MRIs: (2021) unknown result. Therapeutic measures were taken as a result of myasthenia gravis, diplopia.; Sender's Comments: Based on available information, a possible contributory role of BNT162B2 vaccine can not be excluded for the reported events of Myasthenia gravis and Diplopia. The impact of this report on the benefit/risk profile of the Pfizer product is evaluated as part of Pfizer procedures for safety evaluation, including the review and analysis of aggregate data for adverse events. Any safety concern identified as part of this review, as well as any appropriate action in response, will be promptly notified to regulatory authorities, Ethics Committees, and Investigators, as appropriate.